What factors drove the changes in Kiniksa's revenue and profit?

What is the revenue and EPS growth rate for Kiniksa year over year?

What does Kiniksa do and what are its main business segments?

What is Kiniksa's gross profit margin?

What guidance did Kiniksa's management provide for the next earnings period?

Did Kiniksa beat or miss consensus estimates last quarter?

What is Kiniksa's latest dividend and current dividend yield?

What were the key takeaways from Kiniksa’s earnings call?

- **Revenue Growth**: ARCALYST up 65% YoY in Q4, full year $677.6M, driven by IL-1 inhibition adoption.
- **Pipeline Momentum**: KPL-387 Phase II enrollment ongoing, targeting 2028-2029 approval; KPL-1161 set to enter clinic.
- **Market Expansion**: 18% penetration in 2+ recurrence population, 20% first recurrence prescriptions, 75% patient preference for KPL-387.
- **Financial Strength**: $414M cash, $59M net income in 2025, guiding to $900M-$920M 2026 revenue.

**【CEO Summary Section】**
- ARCALYST revenue grew 65% YoY to $202.1M in Q4 2025 and 62% to $677.6M for the full year, driven by IL-1 inhibition adoption in recurrent pericarditis.
- KPL-387 Phase II trial enrollment ongoing, targeting monthly dosing with auto-injector; Phase III data expected in 2028-2029.
- KPL-1161 Fc-modified IL-1 inhibitor set to enter clinic by end-2026.
- 2026 net revenue guidance: $900M-$920M, despite Q1 seasonal headwinds.

**【COO Commercial Execution】**
- ARCALYST penetration in 2+ recurrence population reached 18% at end-2025 (vs. 13% in 2024), with 20% of prescriptions for first recurrence patients.
- Digital marketing and AI-driven targeting to expand reach; 4,150 prescribers wrote ARCALYST in 2025, 1,200+ for multiple patients.
- Average therapy duration 3+ years, strong adherence and payer approval rates.

**【CFO Financial Commentary】**
- Full year 2025 net income $59M vs. $43.2M loss in 2024; cash balance $414.1M, generating $170.4M net cash flow.
- ARCALYST collaboration profit grew 96% YoY to $459M, reflecting higher royalty share of revenue.
- Operating expenses up due to ARCALYST growth, SG&A investments in commercial infrastructure.

**【Q&A Highlights】**
- **Pipeline Strategy**: KPL-387 could address 75% of recurrent pericarditis patients preferring monthly dosing; >90% physicians likely to prescribe.
- **Market Dynamics**: 20% first recurrence prescriptions reflect earlier treatment paradigm shift; no difference in persistence rates vs. multiple recurrence patients.
- **FDA Engagement**: KPL-387 Phase II/III program aligned with FDA; Phase III design similar to ARCALYST's RHAPSODY trial.
- **Financial Flexibility**: $414M cash balance supports R&D and M&A; no near-term dilution plans.

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 ARCALYST revenue up 61% YoY to $180.9M, with full-year guidance raised to $670-675M.
- **Market Penetration**: 15% of 2+ recurrence patients treated, 20% scripts for first recurrence.
- **Pipeline Momentum**: KPL-387 Phase II/III trial on track for 2026 readout; 300mg subQ dose validated.
- **Financial Strength**: $352M cash balance, 118% YoY growth in collaboration profit.
- **Patient Retention**: 45% restart rate within 8 weeks, average therapy duration 32 months.

**【CEO Opening Remarks】**
- ARCALYST revenue grew 61% YoY to $180.9M in Q3, driving full-year guidance update to $670-675M (from $625-640M). 
- 15% penetration of the 2+ recurrence patient population, with 20% of prescriptions for first recurrence.
- KPL-387 Phase II/III trial on track for H2 2026 readout, with FDA Orphan Drug Designation granted.

**【CFO Financial Commentary】**
- Collaboration profit rose 118% YoY to $126.6M, reflecting strong ARCALYST adoption.
- Net income of $18.4M vs. $12.7M loss YoY, with cash balance increasing to $352.1M.
- Gross-to-net rate stable at 8.9%, in line with seasonal trends.

**【Q&A Highlights】**
- 45% of patients restarted therapy within 8 weeks, with average duration of 32 months.
- ACC guidelines affirm IL-1 inhibition as steroid-sparing standard of care.
- KPL-387 Phase II dose-finding study confirms 300mg subcutaneous monthly dosing.
- 3,825 prescribers (28% writing >2 scripts), with 80% of scripts for 2+ recurrence patients.

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript

- **Revenue Growth Milestone**: ARCALYST Q2 revenue of $156.8M (+52% YoY), full-year guidance raised to $625-640M.
- **Pipeline Progress**: KPL-387 Phase II/III trial recruiting, targeting 2028-2029 launch with monthly dosing.
- **Financial Strength**: $307.8M cash balance, net income of $17.8M, and 75% YoY growth in collaboration profit.
- **Market Leadership**: 15% penetration in multiple recurrence population, 85% patient compliance, and 90%+ payer approvals.


**【CEO Summary Section】**
- ARCALYST net revenue reached $156.8 million in Q2 2025, a 52% year-over-year increase, with full-year guidance raised to $625-640 million.
- KPL-387 Phase II/III trial for recurrent pericarditis is recruiting, targeting a monthly dosing profile with potential launch in 2028-2029.
- ARCALYST has generated over $1 billion in cumulative sales since launch, driven by its position as the only FDA-approved therapy for recurrent pericarditis.

**【CFO Financial Commentary】**
- ARCALYST revenue grew 52% YoY to $156.8 million, with collaboration profit up 75% YoY to $104.8 million.
- Net income improved to $17.8 million (Q2 2025) from a net loss of $3.9 million (Q2 2024), supported by a $307.8 million cash balance.
- Operating expenses increased 26% YoY, driven by commercial expansion and pipeline development.

**【Q&A Highlights】**
- **ARCALYST Penetration**: 15% of multiple recurrence patients now on therapy, up from 13% at year-end 2024; 20% of prescriptions are for first recurrence.
- **KPL-387 Strategy**: Phase II dose-finding data expected late 2026; targeting monthly dosing in auto-injector for convenience and adherence.
- **Competitive Landscape**: Confident in ARCALYST's leadership as IL-1 inhibitor with 90%+ payer approval rate and 85% patient compliance.
- **Cash Flow Management**: Maintaining annual cash flow positivity while investing in pipeline, with no need for capital market access.


Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: ARCALYST Q1 revenue up 75% YoY to $137.8M, with updated 2025 guidance raised to $590-$605M.
- **Prescriber Expansion**: 300 new prescribers in Q1, total 3,150+ unique prescribers, 820 repeat prescribers.
- **Clinical Momentum**: KPL-387 Phase II/III trial to begin mid-2025; ARCALYST duration increases to 30 months avg.
- **Financial Strength**: Net income $8.5M vs. -$17.7M YoY; $268M cash balance, ~$25M net cash flow Q1.
- **Pipeline Investment**: R&D expenses stable at $16.5M Q1, supporting KPL-387 and KPL-1161 development.

**【Management Opening Remarks】**
- Q1 2025 net product revenue for ARCALYST reached $137.8 million, up 75% YoY, driven by 300 new prescribers and expanded therapy duration (average 30 months vs. 27 months prior). 
- Updated 2025 net sales guidance raised to $590-$605 million (from $560-$580 million) reflecting strong commercial momentum.
- KPL-387 Phase II/III trial expected to begin mid-2025, targeting monthly dosing for recurrent pericarditis.

**【Commercial Update】**
- ARCALYST adoption accelerated despite Q1 specialty drug headwinds, with:
  - 3,150+ unique prescribers (vs. 2,000+ in Q1 2024)
  - 820 repeat prescribers (50% of new scripts)
  - 90%+ payer approval rate
- Medicare Part D changes added ~$10 million in Q1 revenue via co-pay resets, but ~70% of patients remain commercial.
- Patient retention metrics strong: 17-month average initial treatment period, 30-month total duration.

**【Financial Commentary】**
- Net income $8.5 million vs. -$17.7 million YoY, driven by 75% revenue growth outpacing 29% OpEx increase.
- Collaboration profit up 118% YoY to $87.6 million, reflecting commercial scale.
- Cash balance $268.3 million, with ~$25 million net cash flow Q1.
- Tariff impact on Samsung-manufactured ARCALYST limited to ~$0.5 million annually.

**【Q&A Highlights】**
- **Patient Penetration**: 15% of scripts for first recurrence, 85% for 2+ recurrences; 13% market penetration in 2+ recurrences.
- **R&D Costs**: Q1 R&D $16.5 million (flat vs. Q4 2024), excluding $19M one-time charge.
- **Gross-to-Net**: 10.7% Q1 vs. 9.8% FY2024, driven by Medicare Part D conversions.
- **KPL-387 Trial**: Phase II/III design under review with regulators; no ARCALYST switch component disclosed.

Kiniksa Pharmaceuticals (KNSA)-29 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: ARCALYST 2024 net revenue $417M; 2025 guidance $560-580M
- **New Asset Momentum**: KPL-387 Phase II/III starts mid-2025; potential 2028-2029 launch
- **Cash Flow Strength**: $244M cash balance; annual cash flow positive
- **Pipeline Focus**: IL-1 receptor antagonist portfolio with monthly dosing option
- **Market Leadership**: 13% penetration of recurrent pericarditis market

**【CEO Opening Remarks】**
- ARCALYST Q4 2024 net product revenue: $122.5M; full year 2024: $417M
- 2025 ARCALYST net revenue guidance: $560M - $580M
- KPL-387 program: monthly subcu dosing IL-1 receptor antagonist for recurrent pericarditis
- Phase II/III trial start mid-2025; potential approval by 2028-2029
- Discontinuing abiprubart in Sjogren's Disease; exploring strategic alternatives
- Cash flow positive annually; $244M cash balance at year-end

**【CFO Financial Highlights】**
- ARCALYST product revenue YoY growth: 72% Q4, 79% full year
- Collaboration profit YoY growth: 125% Q4, 108% full year
- Net loss: $8.9M Q4, $43.2M full year
- $20M milestone payment from Huadong Medicine for China ARCALYST approval
- 2025 cash flow positive; $37M net cash flow 2024

**【Q&A Key Takeaways】**
1. KPL-387 differentiation: monthly subcu vs weekly ARCALYST; liquid formulation advantage
2. Market potential: 87% patient preference for monthly dosing vs weekly
3. Clinical trial design: Phase II/III non-inferiority vs ARCALYST
4. Regeneron partnership: no non-compete; committed to ARCALYST growth
5. ARCALYST penetration: 13% of target population
6. 2025 R&D spend: ~$100M for KPL-387, KPL-1161, and pipeline

Actual								-0.48	-0.65	-0.66	-0.79	-0.72	-0.61	-0.44	-0.53	-0.36	-0.29	3.23	0.06	-0.18	0.21	-0.2	0.35	-0.25	-0.06	-0.18	-0.12	0.11	0.23	0.23	0.17
Forecast								-0.6325	-0.6	-0.605	-0.636	-0.725	-0.8467	-0.6468	-0.4097	-0.43	-0.455	0.4739	-0.2025	-0.1591	-0.1417	-0.1658	-0.0984	-0.0821	-0.0769	0.0233	0.0241	0.1291	0.2202	0.3236	0.2651
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+24.11%	-8.33%	-9.09%	-24.21%	+0.69%	+27.96%	+31.97%	-29.36%	+16.28%	+36.26%	+581.58%	+129.63%	-13.14%	+248.20%	-20.63%	+455.69%	-204.51%	+21.98%	-872.53%	-597.93%	-14.79%	+4.45%	-28.92%	-35.87%

KNSA

KNSA fundamentals

KNSA Q4 2025 Earnings

Earnings Call

You can ask Aime

KNSA

KNSA fundamentals

KNSA Q4 2025 Earnings

Earnings Call

KNSA Earnings Call Summary for Q4/20258:30 AM on Feb 24, 2026

KNSA Earnings Call Summary for Q3/20258:30 AM on Oct 28, 2025

KNSA Earnings Call Summary for Q2/20258:30 AM on Jul 29, 2025

KNSA Earnings Call Summary for Q1/20258:30 AM on Apr 29, 2025

KNSA Earnings Call Summary for Q4/20248:30 AM on Feb 25, 2025

You can ask Aime